.Attributes Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin led to improved progression-free and general survival, bring about FDA approval and also a new treatment possibility for individuals.